Publication update – Renal cancer national SACT regimen specific consent forms

Dear All,

The consent form project team is pleased to announce that renal cell cancer SACT consent forms have been reviewed and updated. They are now available on the CRUK website at: www.cruk.org/sact_consent.

Please note we have also produced a generic consent form for tyrosine kinase inhibitor and immunotherapy, which can be used in the interim until a regimen specific form for a TKI/IO is available.

Please share this update within your clinical teams or forward to the relevant lead cancer clinician for your organisation.

Any questions please let me know.

Best wishes,
Alia
Alia Nizam |Specialist Oncology Pharmacist. CRUK – Information Lead|
SACT regimen-specific consent forms: www.cruk.org/sact consent |

Latest News

By Joseph Williams on 8th June 2026

BOPA and Pharmaceutical Journal (PJ) Collaboration – Advanced therapy medicinal products: a tsunami in clinical medicine (By BOPA Member – Nisha Shaunak)

This article is brought to you as part of a collaboration with the Pharmaceutical Journal (PJ). The views expressed in this article are those of the author and are not…

Read article
By BOPA E&T Subcommittee on 4th June 2026

SAVE THE DATE: BOPA Introduction to Cancer Course, London, September 2026 – Registration opens soon!

The popular Introduction to Cancer Course is coming to London in September 2026 The BOPA Introduction to Cancer Course 2026 WHEN: Thursday 17th & Friday 18th September 2026 WHERE: University College Hospital,…

Read article
By Macmillan Cancer Support on 4th June 2026

Cancer Information Development team at Macmillan Cancer Support

Dear BOPA members, The Cancer Information Development team at Macmillan Cancer Support would like to make you aware of a couple of new cancer treatment information pages on our website:…

Read article
By Clayton Wong on 1st June 2026

Launch of Bespoke Health Technology Assessment Course

Bespoke CPD Course on Health Technology Assessment (HTA)    We are delighted to see the launch of the BOPA Health Technology Assessment (HTA) course, which represents an important step forward in supporting the cancer pharmacy workforce…

Read article